SetPoint System® is first-of-its-kind neuroimmune modulation device for the treatment of adults living with moderate-to-severe rheumatoid arthritis SetPoint Medical, a commercial-stage medical ...

American corporations SetPoint Medical announced on 31st (local time) that its electroceutical for treating rheumatoid arthritis has received Food and Drug Administration (FDA) approval.

SetPoint Medical to Present Data at ACR Convergence 2025 Demonstrating Sustained Efficacy and Safety for the SetPoint System to Treat Rheumatoid Arthritis Four presentations highlight 12-month ...

NEW HYDE PARK, N.Y. & VALENCIA, Calif.--(BUSINESS WIRE)--Northwell Health and SetPoint Medical today announced that Northwell is the first health system to provide the recent U.S. Food and Drug ...

Fresh after getting the green light from the U.S. Food and Drug Administration, SetPoint Medical raises $140 million to market and distribute its rheumatoid arthritis treatment. SetPoint Medical Chief ...

SetPoint Medical, a Valencia-based company dedicated to developing therapies for people living with chronic autoimmune diseases, raised $140 million in private financing that includes $25 million in ...

SetPoint Medical has secured $140m through private financing, earmarked for the commercial rollout of the SetPoint System, a neuroimmune modulation therapy designed for patients with ...

Shortly after obtaining a green light from the FDA, SetPoint Medical announced $140 million in new funding to juice the commercialization of its neuromodulation implant for rheumatoid arthritis. The ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. SetPoint Medical said Monday that it raised $140 million ...

The U.S. Food and Drug Administration has approved the SetPoint System, a neuroimmune modulation device for the treatment of adults living with moderate-to-severe rheumatoid arthritis (RA). The ...

SetPoint Medical has raised $140 million. This includes $25 million in the second tranche of its Series C financing, as well as $115 million in its Series D financing, co-led by Elevage Medical ...

The SetPoint System is indicated for patients who are not adequately managed by -- or cannot tolerate -- existing advanced RA therapies, such as biological and targeted synthetic disease-modifying ...